| | Independent validation | | | Sample size | Sample size | Discriminative ability of the biomarker | | | Authors | Signature | Clinical utility | Primary IgAN | Healthy controls | Disease controls | Primary IgAN | Healthy controls | Disease controls | Sensitivity | Specificity | AUC (95% CI) | First versus second urine | Urine fraction | Proteomic strategy |
| | Haubitz et al. [6] | 22 proteins/peptides | Diagnostic, potentially predictive | 45 | 57 | 13 (MN) | | | | IgAN versus healthy controls (100%), IgAN versus disease controls (77%) | IgAN versus healthy controls (90%), IgAN versus disease controls (100%) | | Second | Total urine | CE-MS |
| | Julian et al. [52] | 25 peptides | Diagnostic | 45 | 207 | 253 (FSGS, DN, LN, N, amyloidosis, acute vasculitis with nephritis, hypertensive renal disease, MCD, membranous GN) | 10 | 12 | 22 (HSP nephritis, non-IgA GN, IgA-positiveimmune-complexGN) and 5 HSP without nephritis | | IgAN versus healthy and disease controls (82.3%) | | Second | Total urine | CE-MS |
| | Graterol et al. [57] | 16 peptides | Diagnostic | 19 | 14 | No | | | | | | | First | Urine supernatant | MALDI-TOF MS | | 10 peptides | Correlation with poor renal function |
| | Wu et al. [58] | 11 peptides | Diagnostic | 25 | 24 | 23 (MN, MCD, LN) | 7 | 6 | 13 (MN, MCD, LN) | IgAN versus healthy controls (100%), IgAN versus disease controls (85.7%) | IgAN versus healthy controls (100%) IgAN versus disease controls (76.9%) | | First | Urine supernatant | MALDI-TOF MS |
| | Kwak et al. [60] | Alpha-1-antitrypsine isoforms and their fragments elevated in IgAN versus controls | Diagnostic | 8 | 5 | No | | | | | | | First | Urine supernatant | 2-DE and MALDI-TOF-MS |
| | Rocchetti et al. [61] | 13 peptides including Perlecan laminin G-like 3 peptide and free K light chains | Diagnostic | 49 | 40 | 42 (MGN, DN, N) | 14 | | 14 (MN, DN, N) and 10 MPGN | | | | First | Urine supernatant | SELDI-TOF-MS |
| | Siwy et al. [8] | 116 peptides | Discriminating IgAN from dominant CKD | 179 | No | 1001 (FSGS, MCD, MN, DN, N, LN) | 57 | | 417 (FSGS, DN, N, MCD, MN, LN, vasculitis-inducedkidney disease) | | | 0.82 (0.76–0.87) | Second | Total urine | CE-MS |
|
|
